Thermo Fisher Scientific Inc.
NYSE:TMOMedical - Diagnostics & Research
+$4.45 today
- Market cap
- $256.67B
- Beta
- 0.87
- P/E (TTM)
- 25.3
- EPS (TTM)
- $18.44
- Dividend yield
- 0.39%
Volume 1.99M
Average 2.23M
TMO Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Thermo Fisher Scientific Inc.NYSE: TMO
Net Change in Cash · Q3 FY2026 · quarter ended Sep 2026
Net change in cash turns positive
Q3 FY2026 net change in cash was $1.4B, compared with -$2.59B a year earlier. Trailing-twelve-month net change in cash was $2.48B. Over 3 fiscal years it compounded at +13.0% a year.
Context
- Net change in cash amounted to 13.1% of revenue in FY2025, up 3.6 pp from a year earlier.
- Net change in cash increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near $1.4B or moves back toward the trailing-twelve-month quarterly average of $621M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 5.84B USD
- Year-over-year change
- +243.9%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.84B | +243.9% |
| FY2024 | 2024-12-31 | (4.06B) | -822.0% |
| FY2023 | 2023-12-31 | (440M) | -110.9% |
| FY2022 | 2022-12-31 | 4.05B | +169.2% |
| FY2021 | 2021-12-31 | (5.85B) | — |
Net Change in Cash vs competitors
How TMO compares with its peers on the latest reported figures
- TMO's LTM Sep 2026 net change in cash of $2.48B is the 2nd largest of the 10 companies compared; the peer median is $144.8M.
- Its year-over-year change of +193.4% is the 6th highest of 10, against a peer median of +220.8%.
- Net change in cash amounts to 5.2% of revenue for TMO, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $4.16B | +1021.2% | -9.4% | 16.3% | |
| LTM Sep 2026 | $2.48B | +193.4% | +13.0% | 5.2% | |
| LTM Jul 2026 | $223M | +191.0% | — | 3.0% | |
| LTM Sep 2026 | $205.07M | +581.6% | +134.0% | 16.7% | |
| LTM Jul 2026 | $171.62M | +330.6% | — | 3.7% | |
| LTM Jun 2026 | $144.8M | +502.1% | — | 5.6% | |
| LTM Jun 2026 | $93M | +220.8% | — | 2.7% | |
| LTM Jun 2026 | $34.69M | -82.7% | — | 1.7% | |
| LTM Jul 2026 | $30.47M | +111.9% | +18.1% | 1.0% | |
| LTM Jun 2026 | $10.44M | +16.2% | — | 0.3% | |
| Peer median (excluding TMO) | $144.8M | +220.8% | +18.1% | 3.0% | |
Competitors are the stored peer set for TMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.73B | 6.96B | 6B | 6.34B | 6.72B |
| Depreciation & Amortization | 2.59B | 3.38B | 3.41B | 3.11B | 2.78B |
| Deferred Income Tax | (406M) | (995M) | (1.3B) | (1.21B) | (639M) |
| Stock-Based Compensation | 230M | 307M | 278M | 301M | 310M |
| Change in Working Capital | (1.56B) | (1.05B) | (537M) | (334M) | (1.77B) |
| Accounts Receivables | (204M) | (430M) | 209M | (171M) | (426M) |
| Inventory | (1.07B) | (825M) | 598M | (27M) | (74M) |
| Accounts Payables | 479M | 648M | (500M) | 212M | 421M |
| Other Working Capital | (768M) | (442M) | (844M) | (348M) | (1.69B) |
| Other Non-Cash Items | 957M | 550M | 564M | 463M | 412M |
| Operating Cash Flow | 9.54B | 9.15B | 8.41B | 8.67B | 7.82B |
| Capital Expenditures | (2.52B) | (2.24B) | (1.48B) | (1.4B) | (1.53B) |
| Acquisitions (Net) | (19.4B) | (39M) | (3.66B) | (3.13B) | (4.04B) |
| Purchases of Investments | (8M) | (15M) | 0 | (3.4B) | (383M) |
| Sales of Investments | 8M | 15M | 70M | 1.77B | 1.57B |
| Other Investing Activities | (14M) | 123M | (73M) | 317M | 333M |
| Investing Cash Flow | (21.93B) | (2.16B) | (5.14B) | (5.84B) | (4.05B) |
| Debt Repayment | 8.91B | 654M | (155M) | (2.4B) | 5.35B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (2B) | (3B) | (3B) | (4B) | (3B) |
| Dividends Paid | (395M) | (455M) | (523M) | (583M) | (636M) |
| Other Financing Activities | 65M | (9M) | 56M | 194M | 90M |
| Financing Cash Flow | 6.58B | (2.81B) | (3.62B) | (6.79B) | 1.8B |
| Effect of Forex Changes | (37M) | (139M) | (82M) | (91M) | 267M |
| Net Change in Cash | (5.85B) | 4.05B | (440M) | (4.06B) | 5.84B |
| Free Cash Flow | 7.02B | 6.91B | 6.93B | 7.27B | 6.29B |
Thermo Fisher Scientific Inc.
NYSE:TMO
Intrinsic Alpha fair value
Locked
Current Price
$692.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.